retatrutide triple agonist obesity phase 2 trial is gaining attention in metabolic research for its activity on GIP, GLP-1, and glucagon receptors. In this carousel, we summarize recent clinical study findings related to weight management, type Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Description
What if it doesnt work for me?
The FDA has issued a warning to Novo Nordisk over potentially misleading advertising claims related to its weight-loss drug Wegovy
It is one of the incretin-related drugs approved by the MHLW to aid in the treatment of type 2 diabetes
#GLP1 #Biopharma #DrugDevelopment #ObesityInnovation
Find your match!
Learn about appetite rebound, weight regain, and long-term effectsand why bariatric surgery may be a lasting solution.
